Events
Janssen Pharmaceutical, a Johnson & Johnson company, along with Legend Biotech, reported results from their LEGEND-2 Phase I/II clinical trial of CAR-T therapy LCAR-B38M. The therapeutic was being investigated in patients with advanced relapsed or refractory (r/r) multiple myeloma.
At the American Society of Hematology meeting, companies are racing to develop a treatment for SCD, which is an inherited disorder caused by a genetic mutation in the beta-chain of hemoglobin. Some of the data presented by companies were promising, while others reported setbacks.
Seattle Genetics and Takeda show off the impressive survival data that prompted the FDA to give approval to Adcetris for this indication.
Karolinska Development’s portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US.
MorphoSys AG today presented data from the ongoing single-arm phase 2 clinical trial known as L-MIND in an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting 2018 in San Diego, USA.
The year 2018 saw a number of significant triumphs in the biopharma industry – increased numbers of drug approvals and near record-shattering IPOs, but the industry also saw its share of blemishes and black eyes from various corners of the globe.
The idea of throwing Big Pharma under the bus in order to protect innovative biotech companies sparked a robust conversation at the seventh annual Forbes Healthcare Summit.
The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today.
With the American Society of Hematology (ASH) Annual Meeting held this weekend, Celgene and its various collaboration partners had several important presentations.
The conference shed light on varied areas pertaining to reproductive medicine as it explored potential treatment and solutions for Assisted Reproductive Technologies
PRESS RELEASES